Corneal sodium fluorescein staining, measured using a validated clinical scale, at 3 months of · people with meibomian gland dysfunction
It is very uncertain whether IPL (with/without MGX) changes corneal sodium fluorescein staining, measured using a validated… compared with sham or no treatment (with/without MGX) (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Active trachoma · people (any age) with active trachoma
Antibiotic may leads to lower active trachoma Clinical assessment: active trachoma defined as TF,… compared with control (low certainty).
1 finding from 1 review
Ocular chlamydia trachomatis infection · people (any age) with active trachoma
The review found no eligible studies for this question.
1 finding from 1 review
Antibiotics for trachoma 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Antibiotic resistance · people (any age) with active trachoma
Oral azithromycin led to lower antibiotic resistance Proportion of samples showing evidence of… compared with control; GRADE not reported.
1 finding from 1 review
Adverse effects · people (any age) with active trachoma
1 finding from 1 review
Active trachoma · people (any age) with active trachoma
1 finding from 1 review
Ocular chlamydia trachomatis infection · people (any age) with active trachoma
1 finding from 1 review
Antibiotic resistance · people (any age) with active trachoma
The review found no eligible studies for this question.
1 finding from 1 review
Antibiotics for trachoma 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Adverse effects · people (any age) with active trachoma
1 finding from 1 review
Ocular chlamydia trachomatis infection · people (any age) with active trachoma
Antibiotic showed no clear difference in ocular C trachomatis infection Positive test for C trachomatis… compared with control (low certainty).
1 finding from 1 review
Antibiotic resistance · people (any age) with active trachoma
The review found no eligible studies for this question.
1 finding from 1 review
Antibiotics for trachoma 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Adverse effects · people (any age) with active trachoma
Antibiotic may leads to lower adverse effects compared with control (low certainty).
1 finding from 1 review
Active trachoma · people (any age) with active trachoma
Oral showed no clear difference in active trachoma Clinical assessment: active trachoma defined as TF,… compared with topical antibiotic (low certainty).
1 finding from 1 review
Ocular chlamydia trachomatis infection · people (any age) with active trachoma
1 finding from 1 review
Antibiotic resistance · people (any age) with active trachoma
The review found no eligible studies for this question.
1 finding from 1 review
Antibiotics for trachoma 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Adverse effects · people (any age) with active trachoma
1 finding from 1 review
Active trachoma · people (any age) with active trachoma
The review found no eligible studies for this question.
1 finding from 1 review
Antibiotics for trachoma 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
BCVA: gain of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment probably leads to higher gain of 15 or more letters visual acuity at 1 year compared with control (moderate certainty).
1 finding from 1 review
Mean change in visual acuity at 1 year (number of letters) · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in mean change in visual acuity at 1 year (number of letters) compared with ranibizumab (high certainty).
1 finding from 1 review
Reduction in central retinal thickness at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in reduction in central retinal thickness at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review